CAI · XBRL financial data

Caris Life Sciences financial statements, every quarter

The same tables from 5 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (CAI's year ends in late December)

In millions of dollars	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Revenue from contracts with customers	181	217	293*	216	264
Research and development	25	22	32*	31	32
General and administrative	64	52	57*	60	67
Operating income (loss)	(18)	33	88*	5	27
Interest expense	19	14	11*	13	9
Other income (expense)	(18)	(0)	(2)*	0	(25)
Income tax expense (benefit)	0	0	0*	(0)	0
Net income (loss)	(72)	24	82*	(1)	(1)
Earnings per share, basic USD per share	(7.97)	0.09	—	0.00	0.00
Earnings per share, diluted USD per share	(7.97)	0.08	—	0.00	0.00
Weighted average shares, basic millions of shares	65	282	—	283	283
Weighted average shares, diluted millions of shares	65	297	—	283	283

Fiscal quarters (CAI's year ends in late December)

In millions of dollars	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Cash and cash equivalents	719	753	796	820	—
Marketable securities	2	2	2	2	102
Accounts receivable	51	27	112	91	117
Prepaid and other current assets	19	21	22	24	24
Total current assets	833	854	998	1,014	1,058
Property and equipment, net	61	64	63	83	96
Right-of-use asset	—	—	40	—	—
Goodwill	19	19	19	19	19
Total assets	955	985	1,126	1,162	1,230
Accounts payable	29	29	39	70	86
Accrued liabilities	61	57	88	74	105
Current portion of long-term debt	0	0	0	0	0
Total current liabilities	90	86	127	144	191
Long-term debt	374	376	379	381	393
Lease liability, non-current	38	44	42	44	53
Total liabilities	502	506	548	569	638
Accumulated deficit	(2,655)	(2,631)	(2,549)	(2,549)	(2,550)
Total stockholders' equity	453	478	577	593	592
Total liabilities and equity	955	985	1,126	1,162	1,230
Common shares outstanding (cover page) millions of shares	281	282	283	283	283

Fiscal quarters (CAI's year ends in late December)

In millions of dollars	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Net income (loss)	(72)	24	82*	(1)	(1)
Stock-based compensation	28*	14*	13*	16	22*
Depreciation and amortization	6	5	4*	5	7
Net cash from operating activities	7*	62*	45*	33	28*
Purchases of property and equipment	1*	7*	5*	10	—
Net cash from investing activities	(1)*	(7)*	(5)*	(10)	(122)*
Share repurchases	0*	0*	0*	0	21*
Net cash from financing activities	681*	(21)*	3*	1	(37)*
Net change in cash	687*	34*	43*	23	(131)*

SIC 8071 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 8071 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
Caris Life Sciences	not reported	264	28*	282.6M	—	Q2 FY26 10-QJun 30, 2026
Lumexa Imaging Holdings	70	264	33*	96.1M	—	Q2 FY26 10-QJun 30, 2026
RadNet	726	623	94*	78.7M	—	Q2 FY26 10-QJun 30, 2026
Guardant Health	1,053	335	(58)*	134.2M	18.2 quarters	Q2 FY26 10-QJun 30, 2026
GRAIL	56	45	(81)*	44.7M	0.7 quarters	Q2 FY26 10-QJun 30, 2026
Veracyte	300	150	46*	80.4M	—	Q2 FY26 10-QJun 30, 2026
BillionToOne	549	109	9.1*	not reported	—	Q2 FY26 10-QJun 30, 2026
Exact Sciences	956	878*	152*	190.9M	—	Q4 FY25 10-KDec 31, 2025
CareDx	250	139	13*	52.5M	—	Q3 FY26 10-QSep 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.